KALV
Closed
Kalvista Pharmaceuticals Inc
11.59
+0.29 (+2.57%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 11.305
Day's Range: 11.15 - 11.9
Send
sign up or login to leave a comment!
When Written:
7.98
Kalvista Pharmaceuticals Inc is a clinical-stage pharmaceutical company that is focused on the discovery, development, and commercialization of small molecule protease inhibitors for the treatment of diseases with significant unmet medical need. The company's lead product candidate is KVD900, which is being developed for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the hands, feet, face, and airway.
Kalvista Pharmaceuticals was founded in 2009 and is headquartered in Cambridge, Massachusetts. The company's management team has extensive experience in drug discovery and development, and has a track record of successful drug development programs.
In addition to KVD900, Kalvista Pharmaceuticals is also developing a pipeline of other small molecule protease inhibitors for the treatment of various diseases, including diabetic macular edema, diabetic retinopathy, and age-related macular degeneration. The company's goal is to become a leading provider of innovative therapies for patients with serious and chronic diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Kalvista Pharmaceuticals was founded in 2009 and is headquartered in Cambridge, Massachusetts. The company's management team has extensive experience in drug discovery and development, and has a track record of successful drug development programs.
In addition to KVD900, Kalvista Pharmaceuticals is also developing a pipeline of other small molecule protease inhibitors for the treatment of various diseases, including diabetic macular edema, diabetic retinopathy, and age-related macular degeneration. The company's goal is to become a leading provider of innovative therapies for patients with serious and chronic diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








